Identification | Back Directory | [Name]
3-Pyrrolidinamine, 1-(phenylmethyl)-N-[[4-(trifluoromethoxy)phenyl]methyl]- | [CAS]
1321361-13-0 | [Synonyms]
AChE/BChE/BACE-1-IN-1 3-Pyrrolidinamine, 1-(phenylmethyl)-N-[[4-(trifluoromethoxy)phenyl]methyl]- | [Molecular Formula]
C19H21F3N2O | [MOL File]
1321361-13-0.mol | [Molecular Weight]
350.38 |
Hazard Information | Back Directory | [Uses]
AChE/BChE/BACE-1-IN-1 (Compound 4k) is an orally active inhibitor of AChE, BChE, and BACE-1 with IC50 values of 0.058, 0.082 and 0.115 μM against hAChE, hBChE and hBACE-1, respectively. AChE/BChE/BACE-1-IN-1 shows considerable PAS-AChE binding capability, excellent brain permeation, potential disassembly of Aβ aggregates, and neuroprotective activity against Aβ-induced stress. AChE/BChE/BACE-1-IN-1 has remarkable antioxidant potential[1]. | [in vivo]
AChE/BChE/BACE-1-IN-1 (Compound 4k) (0-10 mg/kg; p.o.) ameliorates cognitive dysfunction against the scopolamine-induced amnesia model in the Y-maze test[1]. | [References]
[1] Choubey PK, et al. Design, synthesis, and multitargeted profiling of N-benzylpyrrolidine derivatives for the treatment of Alzheimer's disease. Bioorg Med Chem. 2020 Nov 15;28(22):115721. DOI:10.1016/j.bmc.2020.115721 |
|
|